PAXLOVID.txt 3/24/2023
The evaluation of protease inhibition for COVID-19 in high-risk patients
(EPIC-HR) trial findings indicated that orally administered
nirmatrelvir-ritonavir (Paxlovid) lowered COVID-19-associated
hospitalization risks by 89%
March 21, 2023 - CHECK FOR SIDE EFFECTS.
I've read that it might not be good for CKD patients:
Paxlovid isn't recommended for people with severe kidney or liver
problems. If you have moderate kidney problems, you'll only take
one nirmatrelvir tablet per dose instead of two
Paxlovid isn't recommended for people with severe kidney or liver problems.
If you have moderate kidney problems, you'll only take one nirmatrelvir
tablet per dose instead of two
https://www.goodrx.com/paxlovid/dosage-guide
CHECK WITH YOUR DOCTOR BEFORE TAKING PAXLOVID
https://www.news-medical.net/news/20230321/Paxlovid-is-8025-effective-when-taken-within-5-days-of-severe-COVID.aspx
Everything You Need to Know About Paxlovid
Paxlovid reduces serious risks from Omicron variants
The coronavirus will likely evade Paxlovid eventually
Coronavirus Resource Center - Harvard
Paxlovid = Reduced risk for 10 of 12 long-COVID conditions
Paxlovid May Reduce Long Covid Risk, but Access Is About to Get Worse
You probably know of Paxlovid as an antiviral drug that can help make COVID
infections less severe. Now, a new study found that Paxlovid reduces the
risk of long COVID as well.
They compared outcomes in people who received Paxlovid within 5 days of COVID
symptoms with people who did not receive Paxlovid.
Remember - NOT considered good for Kidney patients - check for other caveats
I am NOT a doctor.
I have had NO medical training of any kind.
I am NOT responsible for what you do, or do not do.
http://www.woodsmall.com/